| Order number | Description | Quantity | Delivery time | CE |
|---|---|---|---|---|
| TB T1102 | TriniCLOT PT HTF 6 ml | 10x6 ml | 1-3 days | x |
TriniCLOT PT HTF 6 mlTriniCLOT PT HTF is a tissue thromboplastin reagent derived from cultured human cells for use in determination of the prothrombin time (PT) in human plasma. The prothrombin time test is used to detect bleeding disorders. An abnormal or extended PT test usually indicates a deficiency in one or more of the factors in the extrinsic or common pathway of blood coagulation. This deficiency can be caused by hereditary coagulation disorders, vitamin K deficiency, liver disease or drug administration. The PT test is commonly used to monitor oral anticoagulant therapy as it is sensitive to deficiency in Factors II, VII and X and for general pre-operative screening. The PT also is used to perform factor assays for the extrinsic system (i.e., Factors II, V, VII and X). The prothrombin time is not sensitive to deficiencies in the intrinsic coagulation system (i.e., Factors VIII, IX, XI and XII), or to platelet dysfunctions. It cannot be used to monitor heparin therapy. Principle of the procedure Thromboplastin activates the extrinsic coagulation pathway in the presence of calcium ions. Addition of tissue thromboplastin containing calcium (TriniCLOT PT HTF) to anticoagulated plasma triggers formation of a fibrin clot. A plasma with a clotting factor deficiency in the extrinsic pathway, will require a longer time than normal samples to form a solid clot. The clotting interval will also be prolonged in plasmas where functional vitamin K dependent factors have been decreased following administration of oral anticoagulants. |
Additional Documentation
|
Login